SEC Form D private-offering filing
Rinascera Therapeutics, Inc.
A new SEC Form D private-offering notice from Boston, MA, a $2,500,000 filer-stated offering target in Biotech. The source filing is one click away.
Clinical stage biotechnology company developing therapies for rare genetic skin diseases, including a topical kinase inhibitor for Gorlin Syndrome and a collagen VII replacement therapy for dystrophic epidermolysis bullosa.
Filed 2025-10-08Filed to raise $2,500,000First money in 2025-09-12Raised so far $2,500,000HQ (as filed) Boston, MASector Biotech ✓Stage (inferred) SeedCall status Delayed filing
Source linked the Form D on EDGAR↗Website verified rinascera.com↗Named in the filing 4 executives & directors
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.